NEW YORK – Molecular diagnostics firm Inflammatix said on Thursday that it has raised $57 million in a Series E funding round.

纽约--分子诊断公司Inflammatix周四表示，该公司已在E轮融资中筹集到5700万美元。

The round was led by Khosla Ventures and Think.Health with participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, and RAW Ventures, among others. The Sunnyvale, California-based firm said that it will use the funding to support regulatory filings and commercialization of its TriVerity Acute Infection and Sepsis Test that is designed for use during triage of patients in emergency departments..

本轮谈判由科斯拉风险投资公司（Khosla Ventures）和Think牵头。Northpond Ventures、D1 Capital Partners、Iberis Capital、Vesalius BioCapital、OSF Healthcare和RAW Ventures等公司的参与。这家总部位于加利福尼亚州桑尼维尔的公司表示，它将利用这笔资金支持其TriVerity急性感染和败血症测试的监管备案和商业化，该测试专为急诊科患者分诊期间使用。。

'The newly raised funds will help us to expand our commercial team and plan clinical interventional and health economic studies as we await FDA clearance over the coming months,' Inflammatix CEO Timothy Sweeney said in a statement.

Inflammatix首席执行官蒂莫西·斯威尼（TimothySweeney）在一份声明中说，在未来几个月等待FDA批准的同时，新筹集的资金将帮助我们扩大商业团队，并计划临床干预和健康经济研究。

Inflammatix secured in 2023 US FDA breakthrough device designation for the TriVerity test, which is a cartridge-based blood test for the differentiation of bacterial, infections, viral infections, and noninfectious disease, with results in 30 minutes. It is also used to predict disease progression in adult patients who have suspected acute infections or sepsis..

Inflammatix于2023年获得美国FDA突破性的TriVerity测试设备名称，该测试是一种基于墨盒的血液测试，用于区分细菌，感染，病毒感染和非感染性疾病，结果在30分钟内完成。它还用于预测疑似急性感染或败血症的成年患者的疾病进展。。

The test cartridge and the company's sample-to-answer Myrna instrument use quantitative real-time RT-LAMP and a machine learning-developed algorithm to analyze 29 mRNA biomarkers, measure a patient's immune response, and generate scores for the likelihood that a patient has a bacterial infection, a viral infection, and a severe illness that will require interventions such as mechanical ventilation or renal replacement therapy within the subsequent seven days..

该测试盒和该公司的样本回答Myrna仪器使用定量实时RT-LAMP和机器学习开发的算法来分析29种mRNA生物标志物，测量患者的免疫反应，并对患者发生细菌感染，病毒感染和严重疾病的可能性进行评分，这些疾病需要在随后的七天内进行机械通气或肾脏替代治疗等干预措施。。

Inflammatix said on Thursday that it has raised more than $200 million in private capital as well as received more than $50 million in grants and contracts from government agencies and foundations. The company announced in 2021 it had closed a $102 million Series D round.

Inflammatix周四表示，它已经筹集了2亿多美元的私人资本，并从政府机构和基金会获得了5000多万美元的赠款和合同。该公司于2021年宣布，已完成1.02亿美元的D轮融资。